Skip to contents

Tobias Schatton, PhD, PharmD
Associate Scientist, Brigham and Women's Hospital
Assistant Professor of Dermatology, Harvard Medical School

Brigham and Women's Hospital
Department of Dermatology
75 Francis Street
Boston, MA 02115

Research Location: Harvard Institute of Medicine

Research Email: tobias.schatton@tch.harvard.edu

Edit Profile


Research Narrative:

Dr. Schatton is currently an Assistant Professor in Dermatology at Harvard Medical School and a faculty member of the Department of Dermatology at Brigham and Women's Hospital in Boston, MA. His laboratory research focuses on stem cell systems of the skin. Dr. Schatton’s objective in the study of human melanoma is to mechanistically dissect how melanoma stem cells impact melanomagenesis, neoplastic progression, and cancer therapeutic resistance, with an emphasis on the immunomodulatory and immunoevasive properties of this novel tumor subpopulation.


Publications (Pulled from Harvard Catalyst Profiles):

1. Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight. 2018 10 18; 3(20).

2. Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018; 7(6):e1435226.

3. Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, Schoppmann SF. Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. Ann Surg Oncol. 2017 Sep; 24(9):2698-2706.

4. Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017 06; 97(6):669-697.

5. Barthel SR, Schatton T. Homing in on the Sweet Side of Immune Checkpoint Biology. Immunity. 2016 05 17; 44(5):1083-5.

6. Kleffel S, Lee N, Lezcano C, Wilson BJ, Sobolewski K, Saab KR, Mueller H, Zhan Q, Posch C, Elco CP, DoRosario A, Garcia SS, Thakuria M, Wang YE, Wang LC, Murphy GF, Frank MH, Schatton T. ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. J Invest Dermatol. 2016 Apr; 136(4):838-846.

7. Schatton T, Schütte U, Frank MH. Effects of Malignant Melanoma Initiating Cells on T-Cell Activation. Methods Mol Biol. 2016 Jan 20.

8. Lee N, Zakka LR, Mihm MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016 Feb; 48(2):177-87.

9. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015 Sep 10; 162(6):1242-56.

10. Schatton T, Yang J, Kleffel S, Uehara M, Barthel SR, Schlapbach C, Zhan Q, Dudeney S, Mueller H, Lee N, de Vries JC, Meier B, Vander Beken S, Kluth MA, Ganss C, Sharpe AH, Waaga-Gasser AM, Sayegh MH, Abdi R, Scharffetter-Kochanek K, Murphy GF, Kupper TS, Frank NY, Frank MH. ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Rep. 2015 Sep 08; 12(10):1564-74.